NextCure Inc. (NASDAQ: NXTC)
$1.76
+0.0900 ( +5.39% ) 133.5K
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.
Market Data
Open
$1.76
Previous close
$1.67
Volume
133.5K
Market cap
$49.79M
Day range
$1.59 - $1.79
52 week range
$0.98 - $2.57
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jun 21, 2024 |
8-k | 8K-related | 14 | Jun 21, 2024 |
4 | Insider transactions | 1 | Jun 21, 2024 |
4 | Insider transactions | 1 | Jun 21, 2024 |
4 | Insider transactions | 1 | Jun 21, 2024 |
4 | Insider transactions | 1 | Jun 21, 2024 |
4 | Insider transactions | 1 | Jun 21, 2024 |
8-k | 8K-related | 15 | Jun 18, 2024 |
8-k | 8K-related | 16 | May 02, 2024 |
10-q | Quarterly Reports | 57 | May 02, 2024 |